140 related articles for article (PubMed ID: 31690096)
41. Compounding warning letters to 503A facilities between 2017 and 2021.
Zhang Q; Liu X; Qian Y; Liu D; Cao L; Li H; Xiao H; Liu W
J Am Pharm Assoc (2003); 2023; 63(5):1583-1591. PubMed ID: 37414280
[TBL] [Abstract][Full Text] [Related]
42. FDA Tackles Underage E-cigarette Use.
Cancer Discov; 2018 Jul; 8(7):OF2. PubMed ID: 29789311
[TBL] [Abstract][Full Text] [Related]
43. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
44. Review of red yeast rice content and current Food and Drug Administration oversight.
Childress L; Gay A; Zargar A; Ito MK
J Clin Lipidol; 2013; 7(2):117-22. PubMed ID: 23415430
[TBL] [Abstract][Full Text] [Related]
45. Narrative Review: The FDA's Perfunctory Approach of Dietary Supplement Regulations Giving Rise to Copious Reports of Adverse Events.
Li W; Wertheimer A
Innov Pharm; 2023; 14(1):. PubMed ID: 38035313
[No Abstract] [Full Text] [Related]
46. Food and Drug Administration surveillance of dermatology-related and nondermatology-related prescription drug advertising in the USA, 2000-2003.
Cowden AL; Katz KA
Br J Dermatol; 2006 May; 154(5):950-8. PubMed ID: 16634900
[TBL] [Abstract][Full Text] [Related]
47. Your business in court and at Federal agencies: 2011-2012.
Reiss JB; Crowder D; McCabe B; DeFeo M; Rifin M; Talbot M
Food Drug Law J; 2013; 68(1):1-51, i. PubMed ID: 24640636
[TBL] [Abstract][Full Text] [Related]
48. Comparison of content of FDA letters not approving applications for new drugs and associated public announcements from sponsors: cross sectional study.
Lurie P; Chahal HS; Sigelman DW; Stacy S; Sclar J; Ddamulira B
BMJ; 2015 Jun; 350():h2758. PubMed ID: 26063327
[TBL] [Abstract][Full Text] [Related]
49. Practice Patterns and Complications of Benign Hysterectomy Following the FDA Statement Warning Against the Use of Power Morcellation.
Multinu F; Casarin J; Hanson KT; Angioni S; Mariani A; Habermann EB; Laughlin-Tommaso SK
JAMA Surg; 2018 Jun; 153(6):e180141. PubMed ID: 29641835
[TBL] [Abstract][Full Text] [Related]
50. Data Integrity: History, Issues, and Remediation of Issues.
Rattan AK
PDA J Pharm Sci Technol; 2018; 72(2):105-116. PubMed ID: 29158286
[TBL] [Abstract][Full Text] [Related]
51. Medical device warning letter draft pilot; availability--FDA. Notice.
Fed Regist; 1998 Aug; 63(166):45821-5. PubMed ID: 10182695
[TBL] [Abstract][Full Text] [Related]
52. Considering the Future of Pharmaceutical Promotions in Social Media Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters".
Carpentier FR
Int J Health Policy Manag; 2016 Feb; 5(4):283-5. PubMed ID: 27239874
[TBL] [Abstract][Full Text] [Related]
53. An analysis of violations of Osha's (1987) occupational exposure to benzene standard.
Williams PR
J Toxicol Environ Health B Crit Rev; 2014; 17(5):259-83. PubMed ID: 25205215
[TBL] [Abstract][Full Text] [Related]
54. Debunking Cannabidiol as a Treatment for COVID-19: Time for the FDA to Adopt a Focused Deterrence Model?
Shover CL; Humphreys K
Cureus; 2020 Jun; 12(6):e8671. PubMed ID: 32699671
[TBL] [Abstract][Full Text] [Related]
55. Assuring Quality of Dietary Supplements for Cancer Patients: An Integrative Formulary Systems Approach.
Lammersfeld CA; Levin MD; Reilly P; Coyne JW; Birdsall TC; Markman M
Integr Med (Encinitas); 2017 Oct; 16(5):38-44. PubMed ID: 30936804
[TBL] [Abstract][Full Text] [Related]
56. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
Roller ST; Pippins RR; Ngai JW
Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
[TBL] [Abstract][Full Text] [Related]
57. Assessing the safety and effectiveness of devices after US Food and Drug Administration approval: FDA-mandated postapproval studies.
Reynolds IS; Rising JP; Coukell AJ; Paulson KH; Redberg RF
JAMA Intern Med; 2014 Nov; 174(11):1773-9. PubMed ID: 25265209
[TBL] [Abstract][Full Text] [Related]
58. Still the Great Debate - "Fair Balance" in Direct-to-Consumer Prescription Drug Advertising Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters".
Rollins BL
Int J Health Policy Manag; 2016 Feb; 5(4):287-8. PubMed ID: 27239875
[TBL] [Abstract][Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
